Abstract
The American Heart Association (AHA) Scientific Sessions 2012 brought together leading experts from around the world to discuss successes and new initiatives aimed at reducing the burden of cardiovascular disease (CVD). A key focus of the meeting was on treatments aimed at preventing cardiovascular events. In addition, the meeting discussed the efficacy of novel therapies and safety of marketed treatments. A review of select late-breaking trials and other presentations will be covered in this article.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call